WindMIL Therapeutics has announced the appointment of Urvashi Patel, PhD, as Vice President of Regulatory and Quality Systems. In this role, Dr. Patel will provide strategic vision and executional leadership for regulatory and quality functions and establish associated operations.
WindMIL Therapeutics (WindMIL) and the University of Michigan Rogel Cancer Center today announced that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with head and neck squamous cell carcinoma (HNSCC).
WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, announced today that it has been cleared by the U.S. Food and Drug Administration (FDA) to proceed with its Phase 2 study of MILs as a potential treatment for patients with non-small cell lung cancer (NSCLC) who have progressed on an anti-PD-1 containing […]
Since leaving a 25-year career and the president of global pharmaceuticals title at Bristol-Myers Squibb in 2005, Don Hayden has kept himself busy as a consultant and adviser to biopharma companies, sometimes juggling seven or eight board appointments. But after a few months as interim CEO of WindMIL Therapeutics, he’s ready to “substantially pull back” on all those commitments as he transitions to a full-time role.
WindMIL Therapeutics has announced the appointment of Donald J. Hayden, Jr., as CEO.
After spending the past four months as interim CEO of WindMIL Therapeutics, former Bristol-Myers Squibb executive Donald J. Hayden Jr. has accepted the position on a permanent basis.
When Donald Hayden, a 25-year veteran of Bristol-Myers Squibb, joined WindMIL Therapeutics as its executive chairman, he figured he would steer the ship until the company’s board picked a permanent CEO. But as he got to know the company and the marrow-infiltrating lymphocytes from which it takes its name, he “threw his hat into the […]
Cancer immunotherapy company WindMIL Therapeutics Inc. (Baltimore, Md.) said Chairman and interim CEO Donald Hayden will become the permanent CEO.
WindMIL Therapeutics, developers of marrow-infiltrating lymphocytes for cancer, has established new leadership positions, promoting Chief Scientific Officer Kimberly Noonan to executive VP and CSO, and operations VP Patrick Dougherty to VP of planning and operations. Noonan also serves as a scientific co-founder of WindMIL.
WindMIL Therapeutics has announced the promotions of Kimberly Noonan, PhD, MPH, to Executive Vice President and Chief Scientific Officer and Patrick Dougherty to Vice President, Planning and Operations. Noonan previously served as Chief Scientific Officer and Dougherty as Vice President, Operations.